Alexion announces acquisition of Taligen Therapeutics Alexion Pharmaceuticals.

‘Taligen’s talented researchers and amazing technology will enhance Alexion‘s world-class staff and breakthrough study and development programs, substantially increasing our capability to develop first-in-class therapies for sufferers with severe diseases,’ said Leonard Bell, M.D., CEO of Alexion. ‘As product development opportunities continue to expand, we anticipate increasing the product quality, speed, and throughput of our combined current and long term development programs for the advantage of patients worldwide.’ Taligen’s scientific staff will type the nucleus of Alexion’s brand-new Cambridge Massachusetts-based Translational Medication Group, headed by Abbie Celniker, Ph.D., previous CEO of Taligen and Head of Translational Medication at Alexion now.Both organizations started the study drug at a median of 11.3 hours following the start of upper body pain. In the clopidogrel group, taking into account both randomized and open-label treatment, 79.1 percent of individuals received at least 300 mg, and 19.6 percent at least 600 mg, of clopidogrel between your time of the index event and up to a day after randomization. Premature discontinuation of the study drug was slightly more prevalent in the ticagrelor group than in the clopidogrel group . The overall rate of adherence to the study drug, as assessed by the site investigators, was 82.8 percent, and the median duration of exposure to the analysis drug was 277 times .